A phase II study of neoadjuvant abemaciclib (LY2835219) in postmenopausal women with hormone receptor positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (neoMONARCH)

被引：2
|
作者：
Hurvitz, Sara A.
Schilder, Jeanne Marie
Frenzel, Martin
Martin, Miguel
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-CT092
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT092
引用
收藏
页数：4
相关论文
共 50 条
  • [1] A phase III study of abemaciclib (LY2835219) combined with fulvestrant in women with hormone receptor positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (MONARCH 2)
    Llombart, Antonio
    Toi, Masakazu
    Klise, Suzanne R.
    Frenzel, Martin
    Chan, Edward M.
    Sledge, George W.
    CANCER RESEARCH, 2015, 75
  • [2] Final results of NeoMONARCH: A phase 2 neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive (HR+), HER2 negative breast cancer (BC)
    Martin, Miguel
    Hurvitz, Sara A.
    Chan, David
    Fernandez-Abad, Maria
    Petru, Edgar
    Rostorfer, Regan
    Guarneri, Valentina
    Huang, Chiun-Sheng
    Press, Michael F.
    Costigan, Timothy M.
    Caldwell, Charles W.
    Wijayawardana, Sameera
    Turner, P. Kellie
    Barriga, Susana
    Slamon, Dennis J.
    CANCER RESEARCH, 2018, 78 (04)
  • [3] Patients' preferences for postmenopausal hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer treatments in Japan
    Omori, Y.
    Enatsu, S.
    Cai, Z.
    Ishiguro, H.
    CANCER RESEARCH, 2019, 79 (04)
  • [4] Patterns of disease management for European postmenopausal women with hormone-receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer
    Marinsek, N.
    Andre, F.
    Neven, P.
    Zhang, J.
    Degun, R.
    Benelli, G.
    Saletan, S.
    Jerusalem, G.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S411 - S411
  • [5] A phase 1 study of abemaciclib and niraparib as neoadjuvant therapy in hormone receptor positive (HR+) HER2 negative (HER2-) breast cancer
    Li, Allen
    Naik, Arpana
    Johnson, Nathalie
    Goodyear, Shaun
    Johnson, Brett
    Park, Byung
    Corless, Christopher
    Gray, Joe
    Mills, Gordon
    Mitri, Zahi
    CANCER RESEARCH, 2021, 81 (04)
  • [6] Hormone receptor positive (HR plus )/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer: Sequencing of chemotherapy and endocrine therapy
    Engel-Nitz, Nicole M.
    Hao, Yanni
    Rogerio, Jaqueline Willemann
    Turnbull, James D.
    Rey, Gabriel Gomez
    Sullivan, Jane
    Rossof, Arthur H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [7] A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)
    Rugo, H.
    Tolaney, S.
    Dickler, M.
    Kabos, P.
    Ho, C-L
    Wildiers, H.
    Jerusalem, G.
    Ales-Martinez, J. E.
    Hossain, A.
    Johnston, E.
    Gianni, L.
    CANCER RESEARCH, 2017, 77
  • [8] Markers of response to CDK4 & 6 inhibition from neoMONARCH: A phase II neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive, HER2 negative breast cancer
    Hurvitz, S.
    Martin, M.
    Wijayawardana, S.
    Brahmachary, M.
    Ebert, Pj
    Young, S.
    Jansen, V.
    Slamon, D.
    CANCER RESEARCH, 2019, 79 (04)
  • [9] Interim results from neoMONARCH: A neoadjuvant phase II study of abemaciclib in postmenopausal women with HR +/HER2-breast cancer (BC)
    Hurvitz, S.
    Abad, M. F.
    Rostorfer, R.
    Chan, D.
    Egle, D.
    Huang, C-S.
    Barriga, S.
    Costigan, T. M.
    Caldwell, C. W.
    Schilder, J. M.
    Press, M. F.
    Slamon, D.
    Martin, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer
    Engel-Nitz, Nicole M.
    Johnson, Mary G.
    Johnson, Michael P.
    Cha-Silva, Ashley S.
    Kurosky, Samantha K.
    Liu, Xianchen
    PATIENT PREFERENCE AND ADHERENCE, 2023, 17 : 1049 - 1062
12345